Resmetirom + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Trial Timeline
Dec 29, 2025 → Dec 1, 2027
NCT ID
NCT07335601About Resmetirom + Placebo
Resmetirom + Placebo is a phase 2 stage product being developed by Madrigal Pharmaceuticals for MASH - Metabolic Dysfunction-Associated Steatohepatitis. The current trial status is active. This product is registered under clinical trial identifier NCT07335601. Target conditions include MASH - Metabolic Dysfunction-Associated Steatohepatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07335601 | Phase 2 | Active |
| NCT05500222 | Phase 3 | Active |
Competing Products
6 competing products in MASH - Metabolic Dysfunction-Associated Steatohepatitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3849891 + Placebo | Eli Lilly | Phase 1 | 33 |
| RO7790121 | Roche | Phase 1 | 33 |
| Placebo + IBI362 | Innovent Biologics | Phase 2 | 51 |
| ALN-HSD + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Denifanstat + Placebo | Sagimet Biosciences | Phase 3 | 69 |
| TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US) | Sagimet Biosciences | Phase 2 | 44 |